3SBio (HKSE:01530) Cash Flow from Investing: HK$-2,030 Mil (TTM As of Dec. 2025)


HKSE:01530 3SBio Inc HKSE:01530
92 GF Score
Price HK$16.42
GF Value HK$13.94
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio Cash Flow from Investing?

3SBio HKSE:01530 -0.06% 92 Cash Flow from Investing is HK$-2,030 Mil as of Dec. 2025. GuruFocus rates HKSE:01530 with a GF Score™ of 92/100 and a GF Value™ of HK$13.94 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Dec. 2025, 3SBio spent HK$358 Mil on purchasing property, plant, equipment. It gained HK$1 Mil from selling property, plant, and equipment. It spent HK$0 Mil on purchasing business. It gained HK$0 Mil from selling business. It spent HK$8,584 Mil on purchasing investments. It gained HK$5,861 Mil from selling investments. It paid HK$67Mil for net Intangibles purchase and sale. And it received HK$825 Mil from other investing activities. In all, 3SBio spent HK$2,323 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Dec. 2025.


3SBio  (HKSE:01530) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

3SBio's purchase of property, plant, equipment for the six months ended in Dec. 2025 was HK$-358 Mil. It means 3SBio spent HK$358 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

3SBio's sale of property, plant, equipment for the six months ended in Dec. 2025 was HK$1 Mil. It means 3SBio gained HK$1 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

3SBio's purchase of business for the six months ended in Dec. 2025 was HK$0 Mil. It means 3SBio spent HK$0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

3SBio's sale of business for the six months ended in Dec. 2025 was HK$0 Mil. It means 3SBio gained HK$0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

3SBio's purchase of investment for the six months ended in Dec. 2025 was HK$-8,584 Mil. It means 3SBio spent {stock_data.stock.currency_symbol}}8,584 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

3SBio's sale of investment for the six months ended in Dec. 2025 was HK$5,861 Mil. It means 3SBio gained HK$5,861 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

3SBio's net Intangibles purchase and sale for the six months ended in Dec. 2025 was HK$-67 Mil. It means 3SBio paid HK$67 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

3SBio's cash from discontinued investing activities for the six months ended in Dec. 2025 was 0 Mil. It means 3SBio paid HK$0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

3SBio's cash from other investing activities for the six months ended in Dec. 2025 was HK$825 Mil. It means 3SBio received HK$825 Mil from other investing activities.


3SBio Cash Flow from Investing Related Terms


3SBio Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for 3SBio's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3SBio Cash Flow from Investing Chart

3SBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,575.30 -4,157.52 -1,471.52 -1,449.60 -2,026.48

3SBio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.55 -666.26 -788.83 293.73 -2,323.35
HKSE:01530
92GF Score
3SBio Inc HKSE:01530
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3SBio Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

3SBio's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

3SBio's Cash Flow from Investing for the quarter that ended in Dec. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2,030 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of HK$-2,030 Mil mean?
3SBio (HKSE:01530) has a Cash Flow from Investing of HK$-2,030 Mil as of Dec. 2025. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for 3SBio and its competitors.
Is 3SBio's Cash Flow from Investing too high?
3SBio's current Cash Flow from Investing is HK$-2,030 Mil. Overall, 3SBio has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Cash Flow from Investing compare to VRTX and REGN?
3SBio's Cash Flow from Investing of HK$-2,030 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for 3SBio and its competitors. 3SBio's current Cash Flow from Investing is HK$-2,030 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (HKSE:01530) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$13.94, compared to a current price of HK$16.42 — trading 17.8% above its estimated fair value. The current Cash Flow from Investing is HK$-2,030 Mil. 3SBio's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For 3SBio (HKSE:01530), the current Cash Flow from Investing is HK$-2,030 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3SBio (HKSE:01530) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of HK$16.42 is trading 17.8% above its estimated GF Value™ of HK$13.94. GuruFocus considers 3SBio to be Modestly Overvalued.

Key valuation signals for HKSE:01530:

  • Cash Flow from Investing: HK$-2,030 Mil
  • GF Value™: HK$13.94 vs. price of HK$16.42 (17.8% above fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the HKSE:01530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


3SBio Business Description

Other Exchanges TRSBF:USA83B:Germany
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
92GF Score

Get the complete analysis for HKSE:01530

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.42
Price
HK$13.94
GF Value